Haemonetics (HAE) reported quarterly EPS of $1.14, beating the Zacks Consensus Estimate of $1.07 by $0.07. EPS increased modestly versus $1.10 in the prior year. The earnings beat suggests a mild positive near-term read-through for the stock.
Haemonetics (HAE) reported quarterly EPS of $1.14, beating the Zacks Consensus Estimate of $1.07 by $0.07. EPS increased modestly versus $1.10 in the prior year. The earnings beat suggests a mild positive near-term read-through for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
